United States · FDA National Drug Code directory
AMJEVITA
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 55513-400_3657cc39-5ccd-49af-8f85-b622acc243d9
- Product NDC
- 55513-400
- Form
- INJECTION
- Composition / generic term
- adalimumab-atto
- Labeler
- Amgen, Inc
- Marketing category
- BLA
- Marketing start / end (source format)
- 20230131
- Source listing expiry
- 20271231
Source-listed ingredients
- ADALIMUMAB — 40 mg/.8mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 SYRINGE in 1 CARTON (55513-400-01) / .8 mL in 1 SYRINGE · 55513-400-01
- 2 SYRINGE in 1 CARTON (55513-400-02) / .8 mL in 1 SYRINGE · 55513-400-02
- 1 SYRINGE in 1 CARTON (55513-400-91) / .8 mL in 1 SYRINGE · 55513-400-91
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →